Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Premier Health Group Update: Charting 'Strongly Bullish' Movement

Technical analyst Clive Maund examines this potential of the company's stock. The timing was off when we bought this stock back in the fall, as after we bought the price slumped back toward the lows again. What happened was that I had interpreted the pattern forming a...
Streetwise Reports | January 27, 2020 |

The Euro Upswing Paints an Upcoming Opportunity

Like a phoenix from the ashes, the euro has risen recently – and quite sharply so. Does it portend more strength ahead, or what exactly can we expect ahead? The answer features our game plan for the scenario ahead... Let’s recall our Friday&CloseCurlyQ...
Nadia Simmons | January 2, 2020 |

Gold and Oil: Remembering the '70s

Before I get started on my weekly commentary, I want to thank you all for the waterfall of responses to A Boomer's Plea posted last weekend, in what I must confess was my most impassioned missive of a multi-decade writing career. Speaking out as a member of the generat...
Streetwise Reports | April 28, 2020 |

The Next Breakdown And The Setup

If you've been following our research long enough, you'll remember that we often discuss Fibonacci Price Theory and how we use it to try to identify opportunities and trends in the markets. The basic premise of Fibonacci Price Theory is that price is always seeking to establis...
Chris Vermeulen | August 21, 2019 |

Gold and Silver: As We Go from Deflation to Hyperinflation

Technical expert Clive Maund explains why he believes gold and silver are powering up for a stratospheric advance. The deflation and depression is right here, right now, and if you don't believe that, try asking some of the 30 million people who just lost their job...
Streetwise Reports | May 12, 2020 |

Vir Biotech Shares Rise on Joint Research Efforts with the NIH to Combat Coronaviruses

Vir Biotechnology shares traded higher after the company reported that it has entered into a research collaboration with the National Institutes of Health Vaccine Research Center on antibodies against coronaviruses including SARS-CoV-2. Clinical-stage immuno...
Streetwise Reports | March 12, 2020 |

One of the Biggest Short Covering Rallies in History May Be Imminent

Technical analyst Clive Maund considers the opportunities posed by recent market and fiscal news. In recent days the Fed has made it plain that it is prepared to buy anything and everything to prevent imminent total collapse, and you don't have to join man...
Streetwise Reports | March 26, 2020 |

Technical Analyst:Mega-Profitable Strategy for Next Heavy US Stock Market Down Leg Believed Imminent

Technical analyst Clive Maund discusses what he sees ahead for the markets. We are going to look at an array of important factors pointing to another severe drop in the broad U.S. stock market imminently, both factors external to it and indications on the charts fo...
Streetwise Reports | April 2, 2020 |

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shar...
Streetwise Reports | April 13, 2020 |

The Second Massive Downwave Is Almost Upon Us

Technical analyst Clive Maund charts the markets and discusses what he believes is ahead for stocks, the dollar and commodities. Notwithstanding the Fed's seemingly limitless ability to create money to throw at the stock market, which has caused it to rally in rece...
Streetwise Reports | May 5, 2020 |
1 2 3